Dave Allen

Dave Allen is the head of the Respiratory Therapy Area at GSK and is responsible for the identification of novel differentiated medicines and their progression to registration and launch.  He leads a group of over 200 scientists and clinicians who exploit scientific innovations that have the potential to address the major unmet needs in diseases such as COPD, severe asthma, acute lung injury and idiopathic pulmonary fibrosis.

Previously, Dave was head of Respiratory Drug Discovery and prior to that he led the respiratory chemistry department where he managed the lead optimisation portfolio.  He retains a keen interest in chemistry issues and was appointed GSK’s Chief Chemist in 2012.  In this role he works with GSK’s global community of chemists to continually enhance the quality of science and innovation within chemistry at GSK.  In addition, Dave is a member of a number of GSK’s senior decision-making boards within research and development. 

Dave joined GSK as a research chemist in 1981 after completing his MA and BA at Oriel College, Oxford.  During his career he has also worked on discovering antibiotics and cardiovascular medicines, as both a medicinal chemist and project leader.